Stay updated on Cabozantinib And Androgen Ablation in Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib And Androgen Ablation in Prostate Cancer Clinical Trial page.

Latest updates to the Cabozantinib And Androgen Ablation in Prostate Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page’s revision/version banner was updated from v3.5.2 to v3.5.3, reflecting a site software or documentation release rather than a change to the clinical study record content.SummaryDifference0.1%

- Check15 days agoChange DetectedRevision: v3.5.2 has been added and v3.5.0 has been removed.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check44 days agoChange DetectedRevision: v3.5.0 was added. Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check58 days agoChange DetectedRevision: v3.4.3 replaces the previous Revision: v3.4.2 on the page.SummaryDifference0.1%

- Check80 days agoChange DetectedProstate cancer and related topics (MedlinePlus Genetics) were removed, and a new Revision: v3.4.2 tag was added.SummaryDifference0.2%

- Check87 days agoChange DetectedAdded Prostate cancer topic and MedlinePlus Genetics related topics, and updated revision from v3.4.0 to v3.4.1.SummaryDifference0.2%

Stay in the know with updates to Cabozantinib And Androgen Ablation in Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib And Androgen Ablation in Prostate Cancer Clinical Trial page.